Protagenic outlines U.S. trial path for neuropeptide PT00114 after FDA feedback

Protagenic Therapeutics announced August 20 that it had received written responses from the Food and Drug Administration concerning a proposed U.S. clinical program for PT00114, an investigational neuropeptide being developed for generalized anxiety disorder.

According to the company’s Form 8-K, FDA raised no objection to the overall design of a planned three-part Phase 1 program, its dose-escalation approach or its safety-review governance. The company also said the agency considered its proposed manufacturing, nonclinical, potency and product-comparability packages reasonable foundations for an investigational new drug application.

The distinction between feedback and authorization is important. Protagenic has not yet submitted the new IND, FDA has not allowed the proposed study to proceed, and PT00114 is not approved for any indication. The agency’s underlying written responses were not included with the filing, leaving the public dependent on the company’s characterization of the exchange.

What a pre-IND response means

Pre-IND discussions let drug developers ask FDA about evidence needed before human testing in the United States. Topics can include toxicology, manufacturing controls, early trial design and the contents of a future application. FDA describes these interactions as advice intended to improve development plans and reduce the risk of a clinical hold.

They are not an efficacy review or a guarantee that a subsequently filed IND will take effect. Protagenic’s filing expressly cautions that the advice is nonbinding and that FDA could request additional data, raise new questions, impose a clinical hold or otherwise delay the program after reviewing the completed application.

Protagenic plans to submit the IND before the end of 2026 and is targeting initial patient dosing during the first half of 2027. Both milestones remain contingent on FDA review and the completion of manufacturing, chemistry and nonclinical work.

Human evidence is limited to early safety studies

PT00114 has previously been examined in single- and multiple-ascending-dose Phase 1 studies outside the United States. These studies enrolled healthy volunteers rather than people with generalized anxiety disorder, making safety, tolerability and pharmacological behavior—not therapeutic efficacy—the relevant endpoints.

A May 2024 SEC filing described 30 participants across five cohorts in the single-dose study. The company reported no clinically relevant adverse events in that portion. The August 2026 filing says the subsequent multiple-dose study was also completed and that no serious adverse events were reported across the two studies.

Those results remain sponsor-reported. Detailed participant-level data, complete adverse-event tables and peer-reviewed results were not provided with the new filing. A small healthy-volunteer program also cannot establish whether the drug is effective or adequately characterize uncommon, delayed or population-specific safety risks.

A peptide aimed at stress signaling

PT00114 is a synthetic analogue associated with the teneurin C-terminal-associated peptide, or TCAP, family. TCAP peptides are derived from teneurin proteins and have been studied for possible roles in stress signaling, neuronal structure, metabolism and behavior.

Published research supports biological activity in cells and animal models, including interactions with corticotropin-releasing-factor-associated stress responses. That mechanistic background does not establish how PT00114 acts in the human brain or whether changes observed in laboratory models will translate into improvements in anxiety symptoms.

The company has cited activity in animal models of anxiety, depression, substance use and post-traumatic stress. The current regulatory development is narrower: a proposed early U.S. study focused on generalized anxiety disorder. Public details about the planned study’s enrollment, comparator, duration and clinical endpoints were not disclosed in the 8-K.

What comes next

The next verifiable milestone would be submission of the IND, followed by the completion of FDA’s initial review period without a clinical hold. A registered protocol would then be needed to evaluate the trial’s design and prespecified outcomes.

For now, the pre-IND feedback reduces some uncertainty about the company’s proposed development package. It does not demonstrate clinical benefit, establish comprehensive safety or show that FDA agrees PT00114 can treat generalized anxiety disorder.